Skip to main content
Premium Trial:

Request an Annual Quote

Spartan Bioscience to Sell Assets to Finance Firm Casa-Dea

NEW YORK — Spartan Bioscience said on Wednesday that it has agreed to sell off its assets to Canadian private investment fund Casa-Dea Finance.

Ottawa, Ontario-based Spartan, founded in 2005, develops molecular diagnostic technologies including its flagship Spartan Cube, a portable PCR-based analyzer that runs tests for COVID-19, Legionnaires' disease-causing Legionella bacteria, and CYP2C19 mutations.

The transaction is expected to close this month. Additional terms were not disclosed.

"We are thrilled to be acquiring Spartan's revolutionary platform, along with retaining many of the organization's devoted employees," Casa-Dea CEO Darrell Edgett said in a statement.

"Casa-Dea's acquisition will represent not only a material affirmation of our technology's potential, but also, an invaluable opportunity to keep our people, and assets, in Canada," Steve Edgett, who has replaced Paul Lem as Spartan's CEO, added in the statement.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.